No Data
PTC Therapeutics Rallies 18% on EU Authorization Update for Translarna
Edgewise Therapeutics' New $175M Stock Sale Agreement and Previous Termination
Edgewise Therapeutics Files For Mixed Shelf Offering, Size Not Disclosed
Edgewise Therapeutics Files For Mixed Shelf Offering, Size Not Disclosed
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15,
Edgewise Therapeutics (EWTX) Gets a Buy From RBC Capital
Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating
Edgewise Therapeutics (EWTX) has an average rating of buy and price targets ranging from $24 to $48, according to analysts polled by Capital IQ. Price: 19.52, Change: -0.48, Percent Change: -2.40